Deerfield Management HIMS Position
ExitedDeerfield Management exited their position in Hims & Hers Health, Inc. (HIMS) in Q2 2024, after holding the stock for 3 quarters.
The position was first reported in Q4 2023 and has been tracked across 3 quarterly 13F filings.
2 other tracked funds also hold HIMS.
Short interest stands at 45.2% of float with 2.2 days to cover, indicating significant bearish positioning against the stock.
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Full company profile →Short Interest
45.2%
2.2 days to cover
Deerfield Management HIMS Position History
Frequently Asked Questions
Does Deerfield Management own HIMS?
No. Deerfield Management exited their position in Hims & Hers Health, Inc. (HIMS) in Q2 2024. They previously held the stock for 3 quarters.
How many hedge funds own HIMS?
2 specialist biotech hedge funds currently hold HIMS, including Driehaus Capital, Casdin Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy HIMS?
Deerfield Management's position in HIMS was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's HIMS position increasing or decreasing?
Deerfield Management completely exited their HIMS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HIMSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →